I read an article yesterday that QCOR's Angus Russell (or whatever his name is) the CEO of Shire was the 17th highest paid Pharma CEO in 2012. Just a lil info, means nothing.
Someone on this board yesterday stated they thought the shorts would try to pin it at 55 or maybe even 50 becuz of Opex. (Puts) I'm not an option guy so I don't have any idea.
Yep Pat...gotta give ya that. I can remember back when we had a BIG argument about Q's PE ratio. You took all kinds of heck but it has been spot on....so far.
NY Times rehash of CDF and Questcor. There are a couple of new things I hadn't heard before. Also several comments at the end of the article interesting.
Don..Not sure either....yet! But I think I read that RE-034 had "zinc" added. I've read so much tonite can't keep up.
Cerium is the sponsor of this application...Check out twitter for a copy of the application.
Don't see this as a replacement for Acthar.
Raptor Drug: Procysbi for rare genetic condition.
Cystinosis is a rare genetic condition that affects an estimated 500 patients in the United States and about 3,000 patients worldwide. Fatal if not treated in early childhood, cystinosis causes a protein building block called cystine to build up in every cell of the body. The buildup of cystine causes kidney problems, which can cause the body to lose too much sugar, proteins and salts through the urine. Cystinosis may lead to slow body growth and small stature, weak bones and developing and worsening kidney failure. There are three types of cystinosis, the most severe being nephropathic cystinosis, which severely damages the kidneys.
Think Favus was just using Acthar as a comparison to the Procysbi.
Raptor Pharma slides again, Favus reportedly out negative
It's been a rough couple of sessions for Raptor Pharmaceuticals (RPTP) as the shares are off some 9.5% since last Thursday (although still up ~116% YTD).
The company could have done without comments out of Favus, where analysts have reportedly called Procysbi "a situation akin to Acthar Gel, with one major difference: The availability of a substantially cheaper version (Cystagon) of the exact same drug [where the] only difference is dosing frequency."
Also mentioned is UnitedHealth's supposed move to put Procysbi on 2014's excluded drug list.
Summing up, Favus has a question for RPTP investors: "At what price would QCOR trade if a generic version of Acthar Gel was available at a 96% discount?" The firm calls the similarities between RPTP and QCOR "striking."
I've heard that from 3 or 4 sources. Unfortunately all those sources are posters on this message board. If this rumor were true can you imagine all the LAWSUITS that would ensue....Just sayin.
Securities Exchange Act of 1934: Rule 10b-5 -- Employment of Manipulative and Deceptive Devices
It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce, or of the mails or of any facility of any national securities exchange,
a. To employ any device, scheme, or artifice to defraud,
b. To make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading, or
c. To engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person,
in connection with the purchase or sale of any security
They then either:
a. Cover their short position shortly after report is out locking in hefty profits.
b. They let the call options expire that they sold collecting healthy premiums.
c. They exercise the puts and lock in healthy gains or sell the puts at a hefty premium to what they paid profiting healthily.
Then they go long the security as when the company responds with the facts the security is almost likely to recover around 70% of its value in the market – profiting again from the average shareholder.
After stealing money from shareholders as a result of their “market moving” information they disperse the market they move on to the next security.
This is a great model, only if it was legal.